Karyopharm’s Xpovio In Multiple Myeloma Priced At $22,000 Per Four-Week Cycle
Immediate interaction with US FDA after stressful advisory committee facilitated accelerated approval in fourth-line myeloma, company says. Four different dosing regimens will be priced at $22,000 for four weeks.
You may also be interested in...
Subgroup Could Give Xpovio Focused Commercial Opportunity In Endometrial Cancer
Karyopharm’s Phase III SIENDO study showed what analysts called a “modest” progression-free survival improvement overall, but a fourfold improvement in patients with wild-type p53.
Coronavirus Update: Alexion Tests Ultomiris in ARDS
More Phase III trials announced from Alexion and Novartis, while Karyopharm investigates potential of repurposed cancer therapy.
FDA Sarclisa Approval Marks Sanofi's Reentry Into Oncology
The anti-CD38 antibody will face an entrenched rival, J&J's Darzalex, for multiple myeloma.